RGNX Stock — Regenxbio Inc

Regenxbio Inc (RGNX)

Updated October 16, 2026.

RGNX is a Stock. Total return is -77.3% over the past 11.1 years, 436.8 points behind SPY at 359.5%.

Regenxbio Inc. is a clinical-stage biotechnology company developing gene therapies using its proprietary NAV Technology Platform to deliver functional genes for treating genetic diseases including wet age-related macular degeneration, Duchenne muscular dystrophy, and mucopolysaccharidosis types I and II; the company also licenses its platform technology to other pharmaceutical companies and collaborates with AbbVie and Nippon Shinyaku on product development. The company does not currently have an established distribution schedule. This security appeals to investors seeking exposure to early-stage biotech innovation, though investors should be aware that clinical-stage companies carry significant development and regulatory risk.

RGNX performance versus SPY

Price and return data through 2026-10-16.

Total return is -77.3% over the past 11.1 years, 436.8 points behind SPY at 359.5%. Over the past year its total return — price change plus distributions reinvested — is -43.9%. Its deepest 1-year drawdown was 64.6%.

RGNX key facts

Asset type

Stock

Asset class

Equity

Inception date

09/17/2015

Distribution frequency

None

Last close

$6.92 (as of 2026-10-16)

Market cap

$457,141,355

Average volume

1210187.0

Beta

0.933

Payout ratio

0.0%

EPS

$-3.78

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

RGNX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 64.6%.

Who may consider RGNX — and who may not

It is a weaker fit for investors who need monthly cash flow (RGNX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on RGNX

• All tickers starting with R

Tagged: Healthcare.

Frequently asked questions